Serious adverse events · induction of remission in Crohn's disease
Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in serious adverse events compared with lactulose (low certainty).
1 finding from 1 review
Serious adverse events · newly diagnosed patients with myelodysplastic syndromes
1 finding from 1 review
Intervention not reported
Serious adverse events · treating pulmonary TB
The intervention showed no clear difference in serious adverse events (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with neuropathic pain (2 studies in peripheral diabetic neuropathy and 1 study in postherpetic neuralgia)
1 finding from 1 review
Serious adverse events · people with asthma
1 finding from 1 review
no estimate extracted
2013 participants
Very low
Serious adverse events · children with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · patients with pancreatic pseudocysts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · adults aged ≥ 18 years undergoing elective surgery at any surgical site
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · people requiring surgery for chronic pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients with chronic pancreatitis and pancreatic pain
Pregabalin showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · Adults with chronic neuropathic pain
1 finding from 1 review
Serious adverse events · adults with fibromyalgia enrolled in EERW studies
1 finding from 1 review
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
Serious adverse events · children with acute asthma
1 finding from 1 review
Serious adverse events · children with acute asthma
1 finding from 1 review
Intervention not reported
Serious adverse events · adults with fibromyalgia
1 finding from 1 review
Intervention not reported
Serious adverse events · participants with an exacerbation of COPD; people with asthma excluded from our analysis
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review